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Ischemic stroke accounts for the majority of stroke cases and constitutes a major cause
of death and disability in the industrialized world. Inflammation has been reported to
constitute a major component of ischemic stroke pathobiology. In the acute phase
of ischemic stroke, microglia, the resident macrophages of the brain, are activated,
followed by several infiltration waves of different circulating immune cells into the brain.
Among these circulating immune cells, monocytes have been shown to play a particularly
important role. Following their infiltration, monocytes differentiate into potent phagocytic
cells, the monocyte-derived macrophages (MDMs), in the ischemic brain. Initially, the
presence of these cells was considered as marker of an exacerbated inflammatory
response that contributes to brain damage. However, the recent reports are suggesting
a more complex and multiphasic roles of these cells in ischemic stroke pathobiology.
Monocytes constitute a heterogeneous group of cells, which comprises two major
subsets in rodent and three major subsets in human. In both species, two equivalent
subsets exist, the pro-inflammatory subset and the anti-inflammatory subset. Recent
data have demonstrated that ischemic stroke differentially regulate monocyte subsets,
which directly affect ischemic stroke pathobiology and may have direct implications in
ischemic stroke therapies. Here, we review the recent findings that addressed the role
of different monocyte subsets in ischemic stroke pathobiology, and the implications on
therapies.
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INTRODUCTION
Stroke is the third leading cause of death and the first cause of disability in industrialized world.
Ischemic stroke accounts for the majority of stroke cases, whereas the remaining stroke cases
are hemorrhagic (Dirnagl et al., 1999). Regional blood supply disruption initiates the ischemic
cascade that leads to neuronal death and rapid loss of neuronal function (Dirnagl et al., 1999). The
ischemic cascade is characterized by the activation of several signaling pathways that compromise
cell survival and function (Mehta et al., 2007). Ischemic stroke triggers blood-brain barrier (BBB)
breakdown, thus contributing to the secondary progression of ischemic injury by increasing
brain edema and exacerbating the inflammatory response in the sub-acute phase (hours to days
after ischemic stroke onset; Dirnagl et al., 1999; Fagan et al., 2004). The severity of these early
events reduces the capacity of neurons to recover in the chronic phase (days to weeks after
ischemic stroke onset), thus significantly worsening stroke outcomes (Moskowitz et al., 2010).
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Inflammation plays a central role in ischemic stroke
pathobiology (Jin et al., 2010). Following ischemic stroke,
microglia, which are brain resident macrophages, are activated
and circulating immune cells, such as monocytes, neutrophils
and lymphocytes are recruited to injury site (Jin et al., 2010).
Among these immune cells, monocytes that give rise to
macrophages play a particularly important role (Chiba and
Umegaki, 2013). Initially, the presence of monocytes at the
injury site has been suggested to contribute to ischemic injury
exacerbation in the acute phase (minutes to hours after ischemic
stroke onset; Chen et al., 2003). However, the experimental
approaches that aimed at depleting these cells in ischemic stroke
animal models worsened ischemic injury by destabilizing brain
microvasculature (Gliem et al., 2012). These reports outline the
complex and multifaceted role of monocytes in ischemic stroke
pathobiology. As such, this mini-review aims to summarize and
discuss the recent findings that addressed the role of different
monocyte subsets in ischemic stroke pathobiology, which may
have direct implication on stroke therapies.
MONOCYTES
Monocytes, which arise from the hematopoietic system in
the bone marrow (BM), play essential role in the innate
immune responses (Thériault et al., 2015). Monocytes are
incompletely differentiated cells (Geissmann et al., 2010),
which have been shown to possess a highly phagocytic
capacity and to elicit specific responses depending on the
nature of stimuli within their microenvironment (Ginhoux
and Jung, 2014). Therefore, to fulfill their role, monocytes are
equipped with several sophisticated mechanisms that include
scavenger receptors, low-density lipoprotein receptors, toll-like
receptors, chemokine/cytokine receptors, Fcγ receptors and
adhesions molecules (Ginhoux and Jung, 2014). Monocytes
are characterized by the expression of several clusters of
differentiation, such as CD115, CD11c, CD14 and CD16 in
human or CD115, CD11b and Ly6C in rodent (Ginhoux and
Jung, 2014). In parallel, both human and rodent monocytes
express different levels of chemokine receptors, among which
are the chemokine (C-X3-C motif) receptor 1 (CX3CR1) and
chemokine (C-C motif) receptor 2 (CCR2; Auffray et al., 2009).
In human, monocytes are regrouped in three main subsets
based on their CD14 and CD16 expression levels, which are
the classical subset (CD14++CD16−), the intermediate subset
(CD14++CD16+) and the non-classical subset (CD14+CD16++;
Naert and Rivest, 2013). In rodent, monocytes are regrouped
into two main subsets based on chemokine receptor and
Ly6C expression levels, namely the pro-inflammatory subset
(CX3CR1lowCCR2+Ly6Chigh) that has a short half-life and
is actively recruited to inflamed tissues, contributing to the
inflammatory response, and the anti-inflammatory subset
(CX3CR1highCCR2−Ly6Clow) that has a long half-life and is
continuously patrolling the lumen of blood vessel, contributing
to the maintenance of vascular homeostasis (Naert and Rivest,
2013). The specific interaction between each of monocyte subsets
and different brain components has begin to emerge due to
the technical advances that allow discriminating and specifically
manipulating each of these subsets (Thériault et al., 2015).
For instance, the mobilization of pro-inflammatory monocytes
from the BM to blood circulation has been reported to be
totally dependent of CCR2 signaling (Mildner et al., 2009).
Upon mobilization, pro-inflammatory monocytes are capable
of infiltrating the inflamed brain, where they differentiate into
macrophages that are morphologically indistinguishable from
resident microglial cells (Thériault et al., 2015). On the other
hand, the survival of anti-inflammatory monocytes in the BM
has been demonstrated to be dependent on the activity of
the orphan nuclear receptor NR4A1 (Hanna et al., 2011).
Interestingly, NR4A1 has been shown in parallel to be implicated
in the differentiation of pro-inflammatory monocytes into
anti-inflammatory monocytes in the blood circulation (Ginhoux
and Jung, 2014). Upon differentiation, the anti-inflammatory
monocytes have been shown to play an important role in
surveying the vasculature and promoting vascular tissue repair
and healing by eliminating cell debris and toxic elements
(Michaud et al., 2013). In addition, some reports have suggested
that the anti-inflammatory subset is implicated in replenishing
resident perivascular macrophage population (Hanisch and
Kettenmann, 2007).
THE DYNAMIC OF MONOCYTES IN
ISCHEMIC STROKE
Monocytes in the Brain
Microglial cells are rapidly activated within minutes in the
acute phase of ischemic stroke (Taylor and Sansing, 2013).
Once activated, microglia can be polarized to adopt different
phenotypes ranging between two extremes, the classically
activated M1 phenotype that is involved in pro-inflammatory
actions, and the alternatively activated M2 phenotype that is
involved in anti-inflammatory actions and tissue healing (Prinz
and Priller, 2014). Microglial activation peaks 2–3 days following
ischemic onset and persists for several weeks (Denes et al., 2007).
In contrast to microglial cell rapid response, monocyte-derived
macrophages (MDMs) are recruited to the injured brain most
abundantly 3–7 days following ischemic stroke, which coincide
with the chronic phase of ischemic stroke (Breckwoldt et al.,
2008). During the chronic phase of ischemic stroke adaptive
endogenous restorative mechanisms are activated in the brain,
which aim essentially at limiting ischemic damage expansion
(Lo, 2008). These mechanisms include neuronal plasticity and
remodeling, a process in which specialized phagocytic cells,
such as microglia, seem to play an important role (ElAli and
Rivest, 2015). Indeed, the specific ablation of microglial cells
exacerbated post-ischemic stroke injury, thus outlining the role
of these cells in the post-ischemic restorative process (Lalancette-
Hébert et al., 2007). Importantly, the capacity of microglial cells
to mediate these reparative mechanisms was hampered by the
severity of ischemic injury (Denes et al., 2007). Microglial cells
have been reported to be highly vulnerable to severe ischemic
injury, which was shown to compromise cell cycle progression,
and to induce a M1 pro-inflammatory phenotype (Ritzel et al.,
2015). However, MDMs have been reported to be less vulnerable
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to severe ischemic injury and to be implicated essentially in
the early clearance of cell debris within the damaged tissues
7 days following ischemic stroke onset (Ritzel et al., 2015). Taken
together, these observations are highly important, as although
MDMs are morphologically indistinguishable from resident
microglial cells and their function overlaps with microglial cell
function, these cells possess a higher phagocytic capacity (Malm
et al., 2010), which may implicate a more efficacious role in
the post-ischemic neuronal plasticity and remodeling processes.
However, future studies are warranted in order to fully address
this point.
These previous studies did not address the specific role of
monocyte subsets. The emerging evidence is suggesting several
functional differences between monocyte subsets in ischemic
stroke. For instance, CCR2+ pro-inflammatory monocytes have
been shown to early infiltrate the ischemic brain, where
they differentiate into anti-inflammatory patrolling monocytes
(Gliem et al., 2012). The selective depletion of CCR2+ pro-
inflammatory monocytes infiltration into the injured brain,
induced the hemorrhagic transformation of ischemic injury in
mice subjected to transient middle cerebral artery occlusion
(MCAo) due to the excessive bleeding caused by the rupture
of the structurally fragile newly formed vessels within the
infarct border zone (Gliem et al., 2012). These results highlight
a previously unknown role of MDMs in maintaining brain
microvasculature integrity. However the exact contribution of
monocyte subsets is still elusive as it is not clear whether
the differentiation of CCR2+ pro-inflammatory monocytes
(Ly6Chigh) into anti-inflammatory monocytes (Ly6Clow) is
mandatory in this process. In line with these results, a recent
study demonstrated that CCR2+ pro-inflammatory monocytes
(Ly6Chigh) infiltration into the ischemic brain plays a beneficial
role in limiting ischemic injury due to their subsequent
differentiation into M2 anti-inflammatory phenotype MDMs
and their capacity to promote the polarization of adjacent
MDMs/microglia towards a M2 anti-inflammatory phenotype
(Chu et al., 2015). Taken together, these results could
provide new insights into the role of these cells in post-
ischemic angiogenesis. Briefly, in rodent, minutes following
ischemic stroke onset, several genes related to angiogenesis are
upregulated in the brain, namely vascular endothelial growth
factor (VEGF), which is accompanied by an increased formation
of new vessels (Hermann and Zechariah, 2009). However,
the biological significance of such a pro-angiogenic activity
following ischemic stroke is still a matter of debate. Several
hypotheses have been advanced, among which the ‘‘clean-up
hypothesis’’ (Manoonkitiwongsa et al., 2001). This hypothesis
proposes that newly formed vessels following ischemic stroke
acts as tunnels that facilitate the infiltration of MDMs into
the damaged region and the removal of necrotic cells within
this region (Manoonkitiwongsa et al., 2001). For instance, the
authors found out that the density of brain microvasculature
increased only in the border of necrotic areas within the ischemic
region, which was tightly associated to an increased number
of MDMs (Manoonkitiwongsa et al., 2001). In contrast to
the few studies that investigated the implication of CCR2+
pro-inflammatory (Ly6Chigh), the role of anti-inflammatory
monocytes (Ly6Clow) in ischemic stroke has never been
investigated or addressed. However, one study has investigated
the implication of anti-inflammatory monocytes (Ly6Clow)
specific depletion on brain injury following cerebral hypoxia-
ischemia induced by Levine/Vannucci model in adult mice
(Michaud et al., 2014). Anti-inflammatory monocytes (Ly6Clow)
depletion did not affect brain injury (Michaud et al., 2014).
However, Levine/Vannucci model in adult mice does not
constitute an optimal model to investigate ischemic stroke,
as it is not clinically relevant in adults. In order to better
translate the potential of preclinical experimental studies into
clinics, the Stroke Therapy Academic Industry Roundtable
(STAIR) provided several recommendations that highlighted
the necessity of using focal/transient ischemic stroke models
that generate a small infarct and an ischemic penumbra in
order to better represent the clinical situation (Stroke Therapy
Academic Industry Roundtable (STAIR), 1999; Gladstone et al.,
2002). Therefore, future studies using clinically relevant ischemic
stroke models in adult animals are warranted in order to
fully address the specific role of anti-inflammatory monocytes
(Ly6Clow) in the ischemic brain. In one study, the time course of
pro-inflammatory (Ly6Chigh) and anti-inflammatory (Ly6Clow)
infiltration into the ischemic brain of mice subjected to transient
MCAo has been analyzed (Kim et al., 2014). Both monocyte
subsets have significantly infiltrated the ischemic brain beginning
of day 1 following ischemic stroke, peaked at day 3 and then
declined at day 7 (Kim et al., 2014). Interestingly, the recruitment
and infiltration of pro-inflammatory monocytes (Ly6Chigh)
decreased over time, while the recruitment and infiltration of
anti-inflammatory monocytes (Ly6Clow) significantly increased
(Kim et al., 2014). These results clearly highlight the presence of
a dynamic shift in the recruitment and infiltration of monocyte
subsets into the ischemic brain, or probably the differentiation of
pro-inflammatory monocytes (Ly6Chigh) into anti-inflammatory
monocytes (Ly6Clow). As such, it conceivable to speculate, based
on the function of each monocyte subset, that in the acute
phase of ischemic pro-inflammatory monocytes (Ly6Chigh) are
implicated in limiting ischemic stroke damage by eliminating
necrotic cell debris and maintaining brain microvasculature
stability, whereas in the sub-acute and chronic phases of ischemic
stroke anti-inflammatory monocytes (Ly6Clow) are implicated in
tissue remodeling and healing.
Monocytes in the Periphery
Besides triggering brain specific immune responses, ischemic
stroke dynamically modulates the peripheral immune responses,
which directly affect disease pathobiology and development
(Dirnagl et al., 2007; Wang et al., 2007). In human, ischemic
stroke triggered a sustained monocytosis translated by an
increased number of total monocytes in the blood circulation
of ischemic stroke patients (Kaito et al., 2013). Interestingly,
the number of classical monocyte subset (CD14++CD16−),
which is the equivalent of rodent pro-inflammatory monocyte
subset (Ly6Chigh), significantly increased in blood circulation,
whereas the number of the non-classical monocyte subset
(CD14+CD16++), which is the equivalent of rodent anti-
inflammatory monocyte subset (Ly6Clow), significantly
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FIGURE 1 | The regulation of monocyte subsets following ischemic
stroke in rodents. In the acute phase, ischemic stroke does not affect
monocyte subset number in the bone marrow (BM). However, the number of
pro-inflammatory monocyte (Ly6Chigh) subset increases in blood circulation
and the ischemic brain, whereas the number of anti-inflammatory monocyte
(Ly6Clow) subset decreases. In the acute phase, pro-inflammatory monocyte
(Ly6Chigh) subset have been demonstrated to contribute to vascular stability,
eliminating necrotic cells and promoting macrophage/microglia polarization
towards a M2 protective phenotype, whereas anti-inflammatory monocyte
(Ly6Clow) subset may probably contribute to vascular stability. On the other
hand, in the chronic phase, ischemic stroke increases the number of both
pro-inflammatory monocyte (Ly6Chigh) and anti-inflammatory monocyte
(Ly6Clow) subsets in the BM. However, the number of both pro-inflammatory
monocyte (Ly6Chigh) and anti-inflammatory monocyte (Ly6Clow) subsets
decreases. Finally, the number of pro-inflammatory monocyte (Ly6Chigh)
subset decreases, whereas the number of anti-inflammatory monocyte
(Ly6Clow) subset increases. In the chronic phase, most infiltrated
pro-inflammatory monocyte subset (Ly6Chigh) subset probably differentiates
into anti-inflammatory monocyte (Ly6Clow), thus contributing to vascular
stability, eliminating cell debris and contributing to tissue remodeling and
healing (Kim et al., 2014).
decreased (Kaito et al., 2013). This differential regulation
of monocyte subsets in blood circulation of ischemic stroke
patients, namely the increased number of the intermediate
monocyte subset, and the decreased number of the non-
classical monocyte subset in the acute and sub-acute phases of
stroke, strongly correlated with the progression and severity
of brain infarction (Kaito et al., 2013). Interestingly, a recent
study showed that ischemic stroke, which was induced by
MCAo, induces a temporal differential regulation of monocyte
subsets in blood circulation and BM (Kim et al., 2014). More
precisely, ischemic stroke potently increased the number of
pro-inflammatory monocytes (Ly6Chigh) in blood circulation
in the acute phase of ischemic stroke (3 h after ischemic stroke
onset) and decreased their number below pre-ischemic levels
in the sub-acute and chronic phases of ischemic stroke (from
1 to 7 days after ischemic stroke onset; Kim et al., 2014). On
the other hand, ischemic stroke induced a sustained reduction
of anti-inflammatory monocytes (Ly6Clow) during the acute,
sub-acute and chronic phases of ischemic stroke (Kim et al.,
2014). Interestingly, the regulation patterns of monocyte subset
are totally inversed in the BM. Importantly; spleen has been
recently identified as an immediate reservoir of monocytes
(Swirski et al., 2009). The number of the monocytes in the spleen
is significantly higher than those present in blood circulation
(Swirski et al., 2009). It has been previously shown that stroke
induces spleen contraction, which was accompanied by a
reduction in the number of splenic cells (Kim et al., 2014).
Importantly, rat subjected to splenectomy 2 weeks before stroke,
which was induced by permanent MCAo, attenuated brain
injury and reduced the number of infiltrated macrophages
into the ischemic brain, outlining the important of spleen-
derived monocytes in stroke pathobiology (Ajmo et al., 2008).
However, this study did not look into the implication of
different monocyte subsets. In this regard, it has been recently
shown that the number of pro-inflammatory (Ly6Chigh) and
anti-inflammatory (Ly6Clow) monocytes significantly decreased
in the spleen of mice subjected to transient MCAo (Kim
et al., 2014). Interestingly, the reduced number of monocyte
subsets in the spleen strongly correlated with their increased
number in the ischemic brain (Kim et al., 2014). Furthermore,
the accumulation of pro-inflammatory (Ly6Chigh) and anti-
inflammatory (Ly6Clow) monocytes in the brain significantly
decreased in mice subjected to splenectomy just before stroke
induction. However, in this study monocytes reduced infiltration
into the ischemic brain did not affect brain injury. Although
authors concluded that spleen-derived monocytes have little
implication in ischemic injury development in the acute phase,
further studies are warranted in order to fully address the role of
each subset by performing for example splenectomy in chimeric
mice in which each monocyte subset is manipulated. Finally,
the discrepancy between the above-discussed studies may be
related to the specie and stroke model used (i.e., permanent
vs. transient MCAo). Taking together, these observations,
namely the recent experimental studies in rodents (Figure 1)
and clinical investigations in stroke patients (Figure 2), outline
the dynamic nature of ischemic-stroke induced regulation of
monocyte subsets in different organs, which deserves further
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FIGURE 2 | The regulation of monocyte subsets following stroke in humans. In the acute and sub-acute phases, stroke increases the number of classical
monocytes (CD14++CD16−) and intermediate monocytes (CD14++CD16+) in blood circulation. On the other hand, stroke decreases the number of non-classical
monocytes (CD14+CD16++) in blood circulation. Interestingly, the number of intermediate monocytes significantly increases in the blood circulation of patients
presenting a sever injury (progressive infarction). In parallel, the number of non-classical monocytes decreases in the blood circulation of patients presenting
stroke-associated infections (Kaito et al., 2013).
investigation to address its biological implication in ischemic
stroke pathobiology.
CONCLUSION
The overwhelming experimental data are suggesting that
monocyte subsets and MDMs play complex and multiphasic
roles in ischemic stroke pathobiology, displaying beneficial
and adverse effects, which totally depend on injury severity
and time window. These complex and multiphasic roles may
explain the failure of most generalized anti-inflammatory
therapeutic strategies that aim essentially at ‘‘switching-off’’
inflammation following ischemic stroke. The accumulating
evidence is outlining a beneficial role of pro-inflammatory
monocytes (Ly6Chigh) in the acute phase of ischemic stroke
by limiting ischemic injury development, and pointing toward
an important role of anti-inflammatory monocytes (Ly6Clow)
in post-ischemic brain remodeling. These new observations
constitute a new framework to re-evaluate how global post-
ischemic inflammation and more specifically monocyte
subset differential and time/severity-dependent regulation
are implicated in ischemic stroke pathobiology, which may
allow the development of more adaptive and efficacious
therapeutic strategies. In this regard, the overwhelming
experimental findings are suggesting that strategies aiming
at specifically modulating the number and/or activity of each
monocyte subset at a specific time window may lead to the
development of new therapeutic avenues new avenues in
stroke therapies. For example, therapeutic strategies that aim at
specifically boosting CCR2+ pro-inflammatory monocytes
(Ly6Chigh) in the acute phase of ischemic stroke might
limit brain injury progression and exacerbation. In parallel,
therapeutic strategies that aim at specifically stimulating the
activity of anti-inflammatory monocytes (Ly6Clow) in the
sub-acute and chronic phases might promote neurorestoration.
Interestingly, clinical studies have sown that the increased
number of intermediate monocytes (CD14++CD16+) in
blood circulation of stroke patients is associated to brain
injury severity, and the decreased number of non-classical
monocytes (CD14+CD16++) is associated to post-stroke
complications, namely stroke-associated infections. As such,
it is conceivable to speculate that therapeutic strategies that
aim at specifically reducing the number of intermediate
monocytes (CD14++CD16+) in blood circulation in the
acute phase of ischemic stroke, while increasing the number
of non-classical monocytes (CD14+CD16++) might limit
brain injury and reduce the risk of developing post-stroke
complications. Indeed strategies that aim at modulating the
function of monocyte subsets have been shown recently to
be promising in treating neurodegenerative disorders, namely
Alzheimer’s disease (AD), by promoting the elimination
of vascular and parenchymal amyloid-beta (Aβ) toxic
peptides (Michaud et al., 2013; ElAli et al., 2015). Therefore,
the development of ‘‘immunomodulatory strategies’’ that
specifically control the function of each monocyte subset
at the different phases of ischemic stroke constitutes a
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promising approach in stroke therapies. However, to achieve
this goal, further studies that aim at fully addressing the
individual role of each monocyte subset following ischemic
stroke are warranted. These studies should also assess the
implication of stroke risk factors, by including human comorbid
conditions such as hyperlipidemia, which has been shown to
dynamically regulate and modulate the frequency, number
and activity of circulating monocyte subsets (Mosig et al.,
2009; Ley et al., 2011; Kim et al., 2012; Herz et al., 2014,
2015).
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